Found: 22
Select item for more details and to access through your institution.
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 774, doi. 10.1002/ajh.27245
- By:
- Publication type:
- Article
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1510, doi. 10.1002/ajh.26709
- By:
- Publication type:
- Article
Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbα antibodies.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 2, p. 206, doi. 10.1002/ajh.22211
- By:
- Publication type:
- Article
LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β‐catenin/cyclin D1 signaling via PLAGL2.
- Published in:
- Cell Biology & Toxicology, 2022, v. 38, n. 6, p. 979, doi. 10.1007/s10565-021-09628-7
- By:
- Publication type:
- Article
Endocan, a potential prognostic and diagnostic biomarker of acute leukemia.
- Published in:
- Molecular & Cellular Biochemistry, 2014, v. 395, n. 1/2, p. 117, doi. 10.1007/s11010-014-2117-0
- By:
- Publication type:
- Article
Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib.
- Published in:
- Cancer Management & Research, 2020, v. 12, p. 4777, doi. 10.2147/CMAR.S253367
- By:
- Publication type:
- Article
Anti-CD19 chimeric antigen receptor T-cell followed by interferon−a therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1021786
- By:
- Publication type:
- Article
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. 1, doi. 10.3389/fimmu.2021.670088
- By:
- Publication type:
- Article
Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 13, p. 13885, doi. 10.1002/cam4.5922
- By:
- Publication type:
- Article
iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.822805
- By:
- Publication type:
- Article
Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.921587
- By:
- Publication type:
- Article
TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.879471
- By:
- Publication type:
- Article
Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine‐based chemotherapy.
- Published in:
- International Journal of Laboratory Hematology, 2020, v. 42, n. 6, p. 849, doi. 10.1111/ijlh.13299
- By:
- Publication type:
- Article
Plasma Levels of Interleukin 12 Family Cytokines and Their Relevant Cytokines in Adult Patients with Chronic Immune Thrombocytopenia before and after High-Dose Dexamethasome Treatment.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Plasma Levels of Interleukin 12 Family Cytokines and Their Relevant Cytokines in Adult Patients with Chronic Immune Thrombocytopenia before and after High-Dose Dexamethasome Treatment.
- Published in:
- Medical Principles & Practice, 2015, v. 24, n. 5, p. 458, doi. 10.1159/000433472
- By:
- Publication type:
- Article
Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment.
- Published in:
- Disease Markers, 2022, p. 1, doi. 10.1155/2022/4052591
- By:
- Publication type:
- Article
Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
- Published in:
- Oncology Reports, 2023, v. 49, n. 2, p. N.PAG
- By:
- Publication type:
- Article
Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
- Published in:
- Oncology Reports, 2022, v. 47, n. 1, p. N.PAG
- By:
- Publication type:
- Article
Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1.
- Published in:
- Oncology Reports, 2019, v. 41, n. 1, p. 415, doi. 10.3892/or.2018.6797
- By:
- Publication type:
- Article
Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.707191
- By:
- Publication type:
- Article
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.670088
- By:
- Publication type:
- Article
Long non-coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR-135b-5p to target KLF9.
- Published in:
- Molecular Medicine Reports, 2021, v. 24, n. 3, p. N.PAG, doi. 10.3892/mmr.2021.12288
- By:
- Publication type:
- Article